Table of Contents Table of Contents
Previous Page  161 / 812 Next Page
Information
Show Menu
Previous Page 161 / 812 Next Page
Page Background

24th European Congress of Psychiatry / European Psychiatry 33S (2016) S116–S348

S157

EW121

Nalmefene in alcohol use disorder

subjects with psychiatric comorbidity:

A preliminary report

M. Di Nicola

1 ,

, L. De Risio

1

, M. Pettorruso

1

, L. Moccia

1

,

G. Martinotti

2

, L. Janiri

1

1

Institute of Psychiatry and Psychology, Catholic University of Sacred

Heart, Rome, Italy

2

Institute of Psychiatry, Department of Neuroscience and Imaging,

“G. d’Annunzio” University of Chieti-Pescara, Chieti, Italy

Corresponding author.

Introduction

Nalmefene is the first drug approved to reduce alco-

hol consumption in Alcohol Use Disorder (AUD) patients with a

high drinking risk level. There is a high prevalence of concurrent

psychiatric disorders in AUD patients, with an associated increased

morbidity and poorer prognosis.

Objectives

Despite high comorbidity rates, little attention has

been paid to the clinical management of these patients.

Aims

The aims of our studywere to evaluate the use of nalmefene

in AUD patients with psychiatric comorbidity, previously treated

unsuccessfully for alcohol dependence, and to assess reduction in

craving.

Methods

Thirty AUD outpatients (M/F: 19/11) with stabilized

anxiety and affective comorbid disorders were treated with as-

needed nalmefene 18mg plus psychosocial support for 24weeks.

Primary outcome measures were: changes in heavy drinking days

(HDDs) and total alcohol consumption (TAC, g/day). Secondary out-

come measures were: changes in Drinking Risk Level (DRL) and

craving levels (Obsessive-Compulsive Drinking Scale [OCDS] and

Visual Analogue Scale for craving [VASc]).

Results

The reduction of HDDs and TAC over time was significant

(

P

< 0.001). A decrease of DRL was reported. Moreover, a significant

reduction in craving levels was observed (OCDS and VAS crav-

ing scores,

P

<0.001). No patients dropped out of the study due to

adverse events.

Conclusions

As-needed nalmefene was well tolerated and useful

in reducing drinking in AUD patients with stabilized psychiatric

comorbidity that had not responded to previous interventions for

alcohol dependence. Nalmefene also reduced craving, which is

related to the motivation to consume alcohol.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.239

EW122

Substance abuse and quality of life in

chronic hepatitis C patients receiving

antiviral treatment

E. Egmond

1 ,

, G. Oriolo

1

, M. Cavero

1

, K. Langohr

2

, R. Solà

3

,

R. Navines

1

, R. Martin-Santos

1

1

Hospital Clínic, Psychiatry and Psychology, Barcelona, Spain

2

Polytecnic University of Barcelona, Statistics and Operation

Research, Barcelona, Spain

3

Hospital del Mar, Hepatology, Barcelona, Spain

Corresponding author.

Introduction

Chronic hepatitis C virus (HCV) is one of world’s

most important chronic infections. HCV can be treated using

interferon-alpha (IFN ) and ribavirin (RBV). HCV, IFN and RBV

are known to impair mental and physical life quality. Many HCV-

infected individuals have life-prevalence of substance use disorder

(SUD).

Objectives

To study life quality (SF-36) in HCV patients with SUD

history during antiviral treatment.

Methods

SF-36 questionnaire was assessed in 384 HCV patients

at baseline, and at 4, 12, 24, and 48weeks of treatment. ANCOVA

models were used to study the association of SF-36 scores and

potential risk factors at baseline. Risk factors from baseline scores

over time were studied through linear mixed models, adjusting for

baseline scores.

Results

At baseline, SUD men had worse mental (

P

= 0.03) and

physical health (

P

= 0.022), and younger patients had worse social

functioning (

P

= 0.011), and mental (

P

= 0.001) but better physical

health (

P

< 0.001).

Figs. 1 and 2

show the results of mental and

physical life quality during treatment from baseline.

Conclusions

This study emphasizes the decrease in life quality in

HCV patients with SUD before and during antiviral treatment.

Grant

Instituto de Carlos III-FIS: PSICOCIT-PI110/01827,EU “One

way to make Europe”, Ministerio de Economia y Competitividad

(MTM2012-38067-C02-01), and support of SGR/2014/1135.

Fig. 1

Mental component scale during treatment.

Fig. 2

Physical component scale during treatment. Adjusting for

gender, age, HIV co-infection, and history of mood disorders.

Disclosure of interest

The authors have not supplied their decla-

ration of competing interest.

http://dx.doi.org/10.1016/j.eurpsy.2016.01.240

EW123

Challenging patients: Human misery

I. Ganhao

1 ,

, S. Paiva

2

, J. Cardoso

2

1

Qta do Anjo, Portugal

2

Centro Hospitalar Psiquiatrico de Lisboa, Psiquiatria Geral e

Transcultural, Lisbon, Portugal

Corresponding author.